mamaprint test has anyone had it?

chicaroo44
chicaroo44 Member Posts: 18

i have my onco appointment on tomorrow.  when my breast surgeon did my mastectomy she sent some of my tumors over to agendia to do a mamaprint test on them.  i was wondering if anyone else has had this test and if it helped with their treatment program.  i know its fairly new but not that new.  really interested in finding out if anyone else has had it done.

Comments

  • VickiSam
    VickiSam Member Posts: 9,079 Member
    Breast Cancer Doctors - normally perform this test

    MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients


    MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.

     

    Unlike previous generation genomic tests, MammaPrint interrogates all of the critical molecular pathways involved in the breast cancer metastatic cascade. It analyzes 70 critical genes that comprise a definitive gene expression signature and stratifies patients into two distinct groups — low risk or high risk of distant recurrence. With MammaPrint, there are no intermediate results.

     

    Hormonal therapy alone (e.g. Tamoxifen) may be sufficient to further reduce her risk if your patient is Low Risk by MammaPrint, when combined with traditional risk factors. Conversely, if she is High Risk by MammaPrint and has additional risk variables, more aggressive therapy including chemotherapy may be recommended.

     

    With MammaPrint, you gain vital insights into the aggressiveness of your patient’s tumor allowing you to tailor your treatment protocol to your patient’s individual needs.

  • Angie2U
    Angie2U Member Posts: 2,991
    VickiSam said:

    Breast Cancer Doctors - normally perform this test

    MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients


    MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.

     

    Unlike previous generation genomic tests, MammaPrint interrogates all of the critical molecular pathways involved in the breast cancer metastatic cascade. It analyzes 70 critical genes that comprise a definitive gene expression signature and stratifies patients into two distinct groups — low risk or high risk of distant recurrence. With MammaPrint, there are no intermediate results.

     

    Hormonal therapy alone (e.g. Tamoxifen) may be sufficient to further reduce her risk if your patient is Low Risk by MammaPrint, when combined with traditional risk factors. Conversely, if she is High Risk by MammaPrint and has additional risk variables, more aggressive therapy including chemotherapy may be recommended.

     

    With MammaPrint, you gain vital insights into the aggressiveness of your patient’s tumor allowing you to tailor your treatment protocol to your patient’s individual needs.

    I have never heard of this. 

    I have never heard of this.  It sounds like a good test though.